South Korea · Biotechnology startup
South Korea · Intocell
Intocell is a biotechnology company that develops antibody drug conjugate (ADC) platform technologies.
Funding reportedLast round: Series C
What company datasets say Intocell raised
Funding, as reported
Reported in all35Bin the source's currency
Rounds2
Last roundSeries C
Last round dateJan 2021
Investors listed10
Biotechnology in South Korea
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Intocell in front of investors. Or tell us what we have wrong.